Trends in Lipid Screening Among Adults in an Integrated Health Care Delivery System, 2009-2015
| Autor: | Deborah S. Ling Grant, Ronald D. Scott, Jin-Wen Y Hsu, Rong Wei, Susan Boklage, Teresa N. Harrison, T. Craig Cheetham, Shen-Chih Chang, Kristi Reynolds, Victoria Romo-LeTourneau |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty MEDLINE Psychological intervention Pharmaceutical Science Pharmacy 030204 cardiovascular system & hematology California 03 medical and health sciences Young Adult 0302 clinical medicine Risk Factors Diabetes Mellitus Medicine Humans Mass Screening 030212 general & internal medicine Young adult Intensive care medicine Aged business.industry Delivery of Health Care Integrated Health Policy American Heart Association Lipid screening Middle Aged Atherosclerosis Lipids United States Health care delivery Practice Guidelines as Topic lipids (amino acids peptides and proteins) Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Journal of managed carespecialty pharmacy. 24(11) |
| ISSN: | 2376-1032 |
| Popis: | Lipid screening determines eligibility for statins and other cardiovascular risk reduction interventions.To examine trends in lipid screening among adults aged ≥20 years in a large, multiethnic, integrated health care delivery system in southern California.Temporal trends in lipid screening were examined from 2009 to 2015 with an index date of September 30 of each year. Lipid screening was defined as the proportion of eligible members each year who (a) had ever been screened among those aged 20-39 years and (b) had been screened in the previous 6 years for those aged ≥ 40 years. Trends were analyzed by age, gender, and the presence of atherosclerotic cardiovascular disease (ASCVD) or diabetes without ASCVD status.More than 2 million individuals were included each year: 5%-6% had ASCVD (includes those with diabetes), 7%-8% had diabetes without ASCVD, and 87% had neither condition. Among the entire population, lipid screening increased from 79.8% in 2009 to 82.6% in 2015 (P0.0001). Among those with ASCVD or diabetes, lipid screening was 99% across all years. Among those without ASCVD or DM, screening increased from 76.9% in 2009 to 80.0% in 2015 (P0.0001), with higher screening among women compared with men and lower screening among individuals younger than 55 years.Consistently high rates of lipid screening were observed among individuals with ASCVD or diabetes. In individuals without these conditions, screening increased over time. However, there is room to further increase screening rates in adults younger than 55 years.This manuscript and research work was supported by a contractual agreement between the Southern California Permanente Medical Group and Regeneron Pharmaceuticals and Sanofi U.S. Researchers from Regeneron and Sanofi collaborated on the study design, interpretation of data, and writing of the manuscript. Ling Grant, Harrison, Chang, Hsu, Cheetham, Wei, and Reynolds are employed by Kaiser Permanente Southern California. Scott is employed by Southern California Permanente Medical Group. Boklage is employed by Regeneron, and Romo-LeTourneau is employed by Sanofi. Preliminary results from this study were presented at the American Heart Association Scientific Sessions; November 12-16, 2016; New Orleans, LA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|